drugset / Trial / NCT00002383

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

NCT00002383

Phase 1 Completed 80 enrolled Hoffmann-La Roche
Treatment

Summary

To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation administered orally every 8 hours for 4 weeks.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Saquinavir Small molecule 400 mg Oral
Subject Saquinavir Small molecule 600 mg Oral
Subject Saquinavir Small molecule 800 mg Oral
Subject Saquinavir Small molecule 1200 mg Oral